Vertex Financial Statements From 2010 to 2022

VRTX
 Stock
  

USD 288.03  10.80  3.61%   

Vertex Pharmaceutic financial statements provide useful quarterly and yearly information to potential Vertex Pharmaceutic investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Vertex Pharmaceutic financial statements helps investors assess Vertex Pharmaceutic's valuation, profitability, and current liquidity needs.
We have found one hundred twelve available fundamental trend indicators for Vertex Pharmaceutic, which can be analyzed and compared to other ratios and to its competition. Make sure you double-check all of Vertex Pharmaceutic current market performance against the performance between 2010 and 2022 to make sure the company can sustain itself down the road.
Vertex Pharmaceutic Net Income Per Employee is fairly stable at the moment as compared to the past year. Vertex Pharmaceutic reported Net Income Per Employee of 600,538 in 2021. Revenue Per Employee is likely to rise to about 2.1 M in 2022, whereas Earnings before Tax are likely to drop (118.4 M) in 2022.
  
Check Vertex Pharmaceutic financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vertex main balance sheet or income statement drivers, such as Direct Expenses of 975.6 M, Cost of Revenue of 204.4 M or Gross Profit of 1.4 B, as well as many exotic indicators such as Interest Coverage of 53.03, Long Term Debt to Equity of 0.0518 or Calculated Tax Rate of 15.34. Vertex financial statements analysis is a perfect complement when working with Vertex Pharmaceutic Valuation or Volatility modules. It can also supplement Vertex Pharmaceutic's financial leverage analysis and stock options assessment as well as various Vertex Pharmaceutic Technical models . Also, please take a look at the analysis of Vertex Pharmaceutic Correlation against competitors.

Vertex Pharmaceutic Revenues

8.17 Billion

Vertex Pharmaceutic Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets14.5 B13.4 B5.7 B
Increasing
Slightly volatile
Cash and Equivalents7.3 B6.8 B2.4 B
Increasing
Slightly volatile
Investments356.8 M243.8 M452 M
Decreasing
Slightly volatile
Investments Current340 M225.6 M437.2 M
Decreasing
Slightly volatile
Investments Non Current30 M23.3 M25.5 M
Decreasing
Slightly volatile
Deferred Revenue14.9 M14.5 M45.9 M
Decreasing
Slightly volatile
Deposit Liabilities65.7 M66.1 M72.3 M
Decreasing
Slightly volatile
Property Plant and Equipment Net678.1 M628.5 M581.2 M
Increasing
Slightly volatile
Inventory78.1 M89.2 M70.2 M
Increasing
Stable
Trade and Non Trade Receivables195.3 M181 M158.7 M
Increasing
Slightly volatile
Trade and Non Trade Payables46.5 M55.3 M60.9 M
Decreasing
Very volatile
Goodwill and Intangible Assets437.6 M384.9 M374.2 M
Decreasing
Stable
Total Liabilities3.6 B3.3 BB
Increasing
Slightly volatile
Shareholders Equity10.9 B10.1 B3.8 B
Increasing
Slightly volatile
Accumulated Other Comprehensive Income20.6 M19.1 M12.1 M
Increasing
Slightly volatile
Current Assets10.3 B9.6 B3.8 B
Increasing
Slightly volatile
Assets Non CurrentB958.7 M932.4 M
Increasing
Slightly volatile
Current Liabilities2.3 B2.1 B996.7 M
Increasing
Slightly volatile
Liabilities Non Current596.3 M689.5 M749.8 M
Decreasing
Very volatile
Tax Liabilities10.8 M10.9 M11.9 M
Decreasing
Slightly volatile
Total Debt816.4 M756.7 M724.2 M
Increasing
Slightly volatile
Debt Current310.2 M287.5 M181.7 M
Increasing
Slightly volatile
Debt Non Current415.6 M469.2 M536.6 M
Decreasing
Very volatile
Shareholders Equity USD1.3 B1.2 B1.2 B
Increasing
Slightly volatile
Cash and Equivalents USD1.2 B1.1 B911.6 M
Increasing
Slightly volatile
Total Debt USD816.4 M756.7 M724.2 M
Increasing
Slightly volatile
Accounts Payable210.4 M195 M100.1 M
Increasing
Slightly volatile
Receivables1.2 B1.1 B422 M
Increasing
Slightly volatile
Inventories381 M353.1 M142.6 M
Increasing
Slightly volatile

Vertex Pharmaceutic Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Revenues8.2 B7.6 BB
Increasing
Slightly volatile
Cost of Revenue204.4 M189.4 M163.5 M
Increasing
Slightly volatile
Selling General and Administrative Expense420.3 M389.5 M375.2 M
Increasing
Slightly volatile
Research and Development ExpenseB942.9 M888.3 M
Increasing
Slightly volatile
Operating Expenses1.4 B1.3 B1.3 B
Increasing
Slightly volatile
Interest Expense79.1 M73.3 M62.4 M
Increasing
Slightly volatile
Income Tax Expense16.2 M15 M5.2 M
Increasing
Stable
Consolidated Income(104.3 M)(96.6 M)(208.9 M)
Increasing
Stable
Net Income to Non Controlling Interests27.2 M25.2 M(532.2 K)
Increasing
Stable
Net Income2.5 B2.3 B648.8 M
Increasing
Slightly volatile
Net Income Common Stock(139 M)(128.9 M)(208.6 M)
Increasing
Stable
Weighted Average Shares235.3 M257.7 M236.6 M
Increasing
Slightly volatile
Weighted Average Shares Diluted237.3 M259.9 M238.5 M
Increasing
Slightly volatile
Earning Before Interest and Taxes EBIT(17.3 M)(16 M)(138.5 M)
Increasing
Stable
Revenues USD1.7 B1.5 B1.3 B
Increasing
Slightly volatile
Net Income Common Stock USD(139 M)(128.9 M)(208.6 M)
Increasing
Stable
Earning Before Interest and Taxes USD(17.3 M)(16 M)(138.5 M)
Increasing
Stable
Gross Profit1.4 B1.3 B1.2 B
Increasing
Slightly volatile
Operating IncomeB2.8 B612.6 M
Increasing
Slightly volatile
Direct Expenses975.6 M904.2 M358.7 M
Increasing
Slightly volatile

Vertex Pharmaceutic Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Net Cash Flow Investment Acquisitions and Disposals169.1 M156.7 M121.1 M
Increasing
Slightly volatile
Net Cash Flow from Financing(1.5 B)(1.5 B)(146.4 M)
Decreasing
Slightly volatile
Issuance Repayment of Debt Securities (9.2 M)(9 M)(629.7 K)
Increasing
Very volatile
Issuance Purchase of Equity Shares63 M61.4 M117.5 M
Decreasing
Slightly volatile
Net Cash Flow from Investing(367.8 M)(340.9 M)(176.7 M)
Decreasing
Slightly volatile
Net Cash Flow from Operations2.9 B2.6 B885.8 M
Increasing
Slightly volatile
Effect of Exchange Rate Changes on Cash (5.5 M)(5.4 M)(2.7 M)
Decreasing
Slightly volatile
Net Cash Flow or Change in Cash and Cash Equivalents455.6 M422.3 M272.1 M
Increasing
Slightly volatile
Share Based Compensation230.8 M213.9 M186.5 M
Increasing
Slightly volatile
Depreciation Amortization and Accretion44.3 M55.3 M51.7 M
Increasing
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Earnings per Basic Share9.819.092.3996
Increasing
Slightly volatile
Earnings per Diluted Share9.729.012.357
Increasing
Slightly volatile
Earnings per Basic Share USD(0.44)(0.41)(0.9102)
Increasing
Stable
Return on Average Equity26.924.9334(5.6778)
Increasing
Slightly volatile
Return on Average Assets20.0718.59970.9699
Increasing
Slightly volatile
Return on Invested Capital(0.0087)(0.0081)(0.0721)
Increasing
Stable
Gross Margin97.9888.062490.3397
Decreasing
Stable
Profit Margin33.3630.92134.7495
Increasing
Slightly volatile
EBITDA Margin41.4938.45325.0506
Increasing
Slightly volatile
Return on Sales(0.0078)(0.0072)(0.2012)
Increasing
Slightly volatile
Asset Turnover0.540.60150.5319
Increasing
Slightly volatile
Enterprise Value over EBITDA374347177
Increasing
Slightly volatile
Enterprise Value over EBIT(1.5 K)(1.5 K)(755)
Decreasing
Slightly volatile
Price to Earnings Ratio(189)(184)(90.6152)
Decreasing
Slightly volatile
Sales per Share31.7129.392312.0752
Increasing
Slightly volatile
Price to Sales Ratio14.569.5315.4238
Decreasing
Stable
Price to Book Value11.8312.2913.7285
Increasing
Stable
Debt to Equity Ratio0.05180.05050.4442
Decreasing
Slightly volatile
Current Ratio3.814.46343.5007
Increasing
Slightly volatile
Free Cash Flow per Share10.089.34612.971
Increasing
Slightly volatile
Book Value per Share4.254.915.2169
Decreasing
Slightly volatile
Tangible Assets Book Value per Share8.449.419.8205
Decreasing
Very volatile
Total Assets Per Share56.9552.784322.9728
Increasing
Slightly volatile
Cash Flow Per Share11.2110.38793.4162
Increasing
Slightly volatile
Return on Investment30.2628.0515(2.0253)
Increasing
Slightly volatile
Operating Margin39.6336.73032.2177
Increasing
Slightly volatile
Calculated Tax Rate15.3414.2214(124)
Increasing
Stable
Receivables Turnover9.417.49149.4404
Decreasing
Slightly volatile
Inventory Turnover2.812.85293.113
Decreasing
Very volatile
PPandE Turnover7.967.38024.8613
Increasing
Stable
Cash and Equivalents Turnover1.651.18511.7608
Decreasing
Slightly volatile
Accounts Payable Turnover46.6843.265128.0064
Increasing
Slightly volatile
Accrued Expenses Turnover4.524.91274.5855
Increasing
Very volatile
Interest Coverage53.0349.153722.2221
Increasing
Slightly volatile
Long Term Debt to Equity0.05180.05050.3896
Decreasing
Slightly volatile
Quick Ratio3.484.04373.223
Increasing
Slightly volatile
Net Current Assets as percentage of Total Assets47.9455.228745.0665
Increasing
Slightly volatile
Revenue to Assets0.50.56390.4871
Increasing
Slightly volatile

Vertex Pharmaceutic Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Earnings before Tax(118.4 M)(109.7 M)(204.2 M)
Increasing
Stable
Earnings Before Interest Taxes and Depreciation Amortization EBITDA3.1 B2.9 B710.3 M
Increasing
Slightly volatile
Earnings Before Interest Taxes and Depreciation Amortization USD58.9 M54.6 M(83.2 M)
Increasing
Slightly volatile
Market Capitalization17.7 B16.4 B16.9 B
Increasing
Slightly volatile
Enterprise Value17.8 B16.5 B17 B
Increasing
Slightly volatile
Invested Capital1.8 B1.7 B1.7 B
Increasing
Slightly volatile
Average Equity1.2 B1.1 B1.1 B
Increasing
Slightly volatile
Average Assets2.6 B2.4 B2.4 B
Increasing
Slightly volatile
Invested Capital Average1.2 B1.4 B1.5 B
Increasing
Stable
Tangible Asset Value2.5 B2.3 B2.2 B
Increasing
Slightly volatile
Free Cash Flow222.8 M206.5 M33 M
Increasing
Slightly volatile
Working Capital801.1 M935.1 M998.6 M
Decreasing
Very volatile
Revenue Per Employee2.1 M1.9 MM
Increasing
Slightly volatile
Net Income Per Employee647.9 K600.5 K147.8 K
Increasing
Slightly volatile

Vertex Fundamental Market Drivers

Forward Price Earnings17.80
Short Percent Of Float1.41%
Average Daily Volume Last 10 Day1.3M
Shares Short Prior Month3.42M
Average Daily Volume In Three Month1.65M
Date Short Interest15th of July 2022
Fifty Day Average276.78
Two Hundred Day Average241.75

Vertex Upcoming Events

Upcoming Quarterly Report7th of February 2022
Next Financial Report5th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End7th of February 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

About Vertex Pharmaceutic Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Vertex Pharmaceutic income statement, its balance sheet, and the statement of cash flows. Vertex Pharmaceutic investors use historical funamental indicators, such as Vertex Pharmaceutic's revenue or net income, to determine how well the company is positioned to perform in the future. Although Vertex Pharmaceutic investors may use each financial statement separately, they are all related. The changes in Vertex Pharmaceutic's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Vertex Pharmaceutic's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Vertex Pharmaceutic Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Vertex Pharmaceutic. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
Deferred Revenue14.5 M14.9 M
Cost of Revenue189.4 M204.4 M
Revenues7.6 B8.2 B
Revenue to Assets 0.56  0.50 
Revenue Per Employee1.9 M2.1 M
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts. Vertex Pharmaceutic operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 00 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Vertex Pharmaceutic without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Price Transformation Now

   

Price Transformation

Use Price Transformation models to analyze depth of different equity instruments across global markets
All  Next Launch Module

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Also, please take a look at the analysis of Vertex Pharmaceutic Correlation against competitors. Note that the Vertex Pharmaceutic information on this page should be used as a complementary analysis to other Vertex Pharmaceutic's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.

Complementary Tools for Vertex Stock analysis

When running Vertex Pharmaceutic price analysis, check to measure Vertex Pharmaceutic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceutic is operating at the current time. Most of Vertex Pharmaceutic's value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceutic's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Vertex Pharmaceutic's price. Additionally, you may evaluate how the addition of Vertex Pharmaceutic to your portfolios can decrease your overall portfolio volatility.
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Go
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
Money Managers
Screen money managers from public funds and ETFs managed around the world
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Is Vertex Pharmaceutic's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vertex Pharmaceutic. If investors know Vertex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vertex Pharmaceutic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth YOY
11.1
Market Capitalization
75.3 B
Quarterly Revenue Growth YOY
0.23
Return On Assets
0.14
Return On Equity
0.3
The market value of Vertex Pharmaceutic is measured differently than its book value, which is the value of Vertex that is recorded on the company's balance sheet. Investors also form their own opinion of Vertex Pharmaceutic's value that differs from its market value or its book value, called intrinsic value, which is Vertex Pharmaceutic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vertex Pharmaceutic's market value can be influenced by many factors that don't directly affect Vertex Pharmaceutic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vertex Pharmaceutic's value and its price as these two are different measures arrived at by different means. Investors typically determine Vertex Pharmaceutic value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vertex Pharmaceutic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.